Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Sinn, Dong Hyun | - |
dc.contributor.author | Yu, Jung Hwan | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Lee, Jung Il | - |
dc.contributor.author | Lee, Kwan Sik | - |
dc.contributor.author | Lee, Chang Hun | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Kweon, Young Oh | - |
dc.contributor.author | Kang, Wonseok | - |
dc.contributor.author | Paik, Yong-Han | - |
dc.contributor.author | Lee, Jin-Woo | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Kim, Seung Up | - |
dc.date.accessioned | 2021-08-30T19:50:47Z | - |
dc.date.available | 2021-08-30T19:50:47Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/54500 | - |
dc.description.abstract | Background Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant phase. Aims To investigate the cumulative incidence of phase change and hepatocellular carcinoma (HCC) and independent predictors for phase change in patients with CHB in immune-tolerant phase. Methods In total, 946 patients in immune-tolerant phase, defined as hepatitis B e antigen positivity, HBV-DNA >20 000 IU/mL and alanine aminotransferase (ALT) <= 40 IU/L, between 1989 and 2017 were enrolled from eight institutes. Results The mean age of study population (429 men and 517 women) was 36.7 years. The mean ALT and HBV-DNA levels were 24.6 IU/L and 8.50 log(10) IU/mL, respectively. Of the study population, 476 (50.3%) patients remained in immune-tolerant phase throughout the study period (median: 63.6 months). The cumulative incidence rates of phase change and HCC at 10 years were 70.7% and 1.7%, respectively. Multivariate analyses revealed that HBV-DNA level >10(7) IU/mL was associated independently with a reduced risk of phase change (hazard ratio [HR] = 0.734, P = 0.008), whereas a high ALT level, above the cut-off recommended in the Korean Association for the Study of the Liver guidelines (34 IU/L for men and 30 IU/L for women), was associated independently with a greater risk of phase change (HR = 1.885, P < 0.001). Conclusions The criterion of HBV-DNA level > 10(7) IU/mL may be useful to define immune-tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune-tolerant phase. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | T-CELL FUNCTION | - |
dc.subject | NATURAL-HISTORY | - |
dc.subject | HBV DNA | - |
dc.subject | CIRRHOSIS | - |
dc.subject | FIBROSIS | - |
dc.subject | VIRUS | - |
dc.subject | ALT | - |
dc.subject | GUIDELINES | - |
dc.subject | LEVEL | - |
dc.title | Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.identifier.doi | 10.1111/apt.15741 | - |
dc.identifier.scopusid | 2-s2.0-85085643041 | - |
dc.identifier.wosid | 000535275500001 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.52, no.1, pp.196 - 204 | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.title | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.volume | 52 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 196 | - |
dc.citation.endPage | 204 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | T-CELL FUNCTION | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | HBV DNA | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | ALT | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | LEVEL | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.